Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press1702210.36691/RJA17022Letters to the editorПисьма в редакциюMiscellaneousThe past, present, and future of anti-IgE therapyПрошлое, настоящее и будущее анти-IgE терапииhttps://orcid.org/0000-0002-3162-25103363-6170NenashevaNatalya M.НенашеваНаталья Михайловна
Russian Federation

MD, Dr. Sci. (Medicine), Professor

д-р мед. наук, профессор

1444031@gmail.comhttps://orcid.org/0000-0003-3250-06945698-6436KurbachevaOksana M.КурбачеваОксана Михайловна
Russian Federation

MD, Dr. Sci. (Medicine), Professor

д-р мед. наук, профессор

kurbacheva@gmail.comhttps://orcid.org/0000-0003-3358-5087FedenkoElena S.ФеденкоЕлена Сергеевна
Russian Federation

MD, Dr. Sci. (Medicine), Professor

д-р мед. наук, профессор

efedks@gmail.comRussian Medical Academy of Continuous Professional EducationРоссийская медицинская академия непрерывного профессионального образованияNational Research Center — Institute of Immunology Federal Medical-Biological Agency of RussiaГосударственный научный центр «Институт иммунологии»Russian University of MedicineРоссийский университет медицины21042025030620252222262321504202516042025Copyright ©; 2025, ABV-pressCopyright ©; 2025, ИД "АБВ-пресс"2025ABV-pressИД "АБВ-пресс"https://creativecommons.org/licenses/by-nc-nd/4.0/https://rusalljournal.ru/raj/article/view/17022

Immunoglobulin E is the last of the discovered immunoglobulins and is the main mediator of allergic reactions. Its role in allergy pathogenesis led to development of the first immunobiological drug for treatment of allergic diseases — omalizumab. Omalizumab binds free immunoglobulin E, preventing its binding to high-affinity receptors, thereby blocking the cascade of allergic inflammation.

This review discusses the results of the main studies of omalizumab for treatment of severe bronchial asthma, chronic spontaneous urticaria, and other allergic diseases. The drug has been used for more than twenty years, but the research is still ongoing. Thus in 2024, omalizumab was approved for use in prevention of anaphylaxis in patients with food allergies. The drug is being studied in combination with allergen-specific immunotherapy, as well as in patients with allergic bronchopulmonary aspergillosis.

Иммуноглобулин Е — последний из открытых иммуноглобулинов, являющийся основным медиатором аллергических реакций. Его роль в их патогенезе привела к созданию первого иммунобиологического препарата для лечения аллергических заболеваний — омализумаба. Омализумаб связывает свободный иммуноглобулин Е, препятствуя его взаимодействию с высокоаффинными рецепторами, тем самым блокируя каскад аллергического воспаления.

В обзоре рассмотрены результаты основных исследований омализумаба в лечении тяжелой бронхиальной астмы, хронической спонтанной крапивницы и других аллергических заболеваний. Несмотря на более чем 20-летнюю историю применения препарата, его исследования по-прежнему продолжаются. В 2024 г. омализумаб был разрешен к применению для профилактики анафилаксии у пациентов с пищевой аллергией. Продолжается изучение препарата в комбинации с аллергенспецифической иммунотерапией, а также у больных аллергическим бронхолегочным аспергиллезом.

omalizumabasthmaurticariaallergic rhinitisомализумабастмакрапивницааллергический ринитMalveaux FJ, Conroy MC, Adkinson NF, Lichtenstein LM. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Investig. 1978;62(1):176–181. doi: 10.1172/JCI109103MacGlashan D Jr, McKenzie-White J, Chichester K, et al. In vitro regulation of FcεRIα expression on human basophils by IgE antibody. Blood. 1998;91(5):1633–1643.Cruse G, Cockerill S, Bradding P. IgE alone promotes human lung mast cell survival through the autocrine production of IL-6. BMC Immunol. 2008;9:2. doi: 10.1186/1471-2172-9-2 EDN: PEVIYXMaurer D, Ebner C, Reininger B, et al. The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol. 1995;154(12):6285–6290. doi: 10.4049/jimmunol.154.12.6285Holloway JA, Holgate ST, Semper AE. Expression of the high-affinity IgE receptor on peripheral blood dendritic cells: differential binding of IgE in atopic asthma. J Allergy Clin Immunol. 2001;107(6):1009–1018. doi: 10.1067/mai.2001.115039Rajakulasingam K, Durham SR, O’Brien F, et al. Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. J Allergy Clin Immunol. 1997;100(1):78–86. doi: 10.1016/s0091-6749(97)70198-2Domingo C. Omalizumab for severe asthma: efficacy beyond the atopic patient? Drugs. 2014;74(5):521–533. doi: 10.1007/s40265-014-0203-y EDN: SRBWZBPalomares Ó, Sánchez-Ramón S, Dávila I, et al. DIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies. Int J Mol Sci. 2017;18(6):1328. doi: 10.3390/ijms18061328Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18(2):157–162. doi: 10.1038/72601MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158(3):1438–1445. doi: 10.4049/jimmunol.158.3.1438Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593. doi: 10.1164/rccm.200312-1651OCPrussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(6):1147–1154. doi: 10.1016/j.jaci.2003.10.003Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004;114(3):527–530. doi: 10.1016/j.jaci.2004.06.032Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004;113(2):297–302. doi: 10.1016/j.jaci.2003.11.044Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131(1):46–52. doi: 10.1159/000070434Oliver JM, Tarleton CA, Gilmartin L, et al. Reduced FcεRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol. 2009;151(4):275–284. doi: 10.1159/000250436Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol. 2010;125(4):896–901.e6. doi: 10.1016/j.jaci.2009.10.021Takaku Y, Soma T, Nishihara F, et al. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma. Int Arch Allergy Immunol. 2013;161(Suppl 2):107–117. doi: 10.1159/000350852Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi: 10.1111/j.1398–9995.2004.00772.x EDN: MIJIRFBraunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the “real-world” effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. doi: 10.1016/j.rmed.2013.04.017 EDN: RNNADDNormansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;2014(1):CD003559. doi: 10.1002/14651858.CD003559.pub4 EDN: YCKDPNSiergiejko Z, Świebocka E, Smith N, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27(11):2223–2228. doi: 10.1185/03007995.2011.620950 EDN: PLMLZPDomingo C, Moreno A, José Amengual M, et al. Omalizumab in the management of oral corticosteroid-dependent IgE-mediated asthma patients. Curr Med Res Opin. 2011;27(1):45–53. doi: 10.1185/03007995.2010.536208Eisner MD, Zazzali JL, Miller MK, et al. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS study. J Asthma 2012;49(6):642–648. doi: 10.3109/02770903.2012.690477 EDN: RNMZQBChen H, Eisner MD, Haselkorn T, Trzaskoma B. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respir Med. 2013;107(1):60–67. doi: 10.1016/j.rmed.2012.09.008 EDN: RNMZVVPapaioannou AI, Mplizou M, Porpodis K, et al. Long-term efficacy and safety of omalizumab in patients with allergic asthma: a real-life study. Allergy Asthma Proc. 2021;42(3):235–242. doi: 10.2500/aap.2021.42.210014 EDN: TILLXXNamazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020;145(2):528–536.e1. doi: 10.1016/j.jaci.2019.05.019 EDN: CLQTLCVignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy. 2004;59(7):709–717. doi: 10.1111/j.1398-9995.2004.00550.x EDN: FOYUUVYu C, Wang K, Cui X, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. Am J Rhinol Allergy. 2020;34(2):196–208. doi: 10.1177/1945892419884774Pavlova KS, Kulichenko DS, Kurbacheva OM, et al. Omalizumab in the severe exacerbations of seasonal allergic rhinitis. Russian Journal of Allergy. 2022;19(2):164–174. (In Russ.) DOI: 10.36691/RJA1539 EDN: JISZIUMetz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics. 2017;7(5):1266–1276. doi: 10.7150/thno.18304Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–1750.e4. doi: 10.1016/j.jaci.2015.12.1342Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2019;155(1):29–38. doi: 10.1001/jamadermatol.2018.3447 EDN: XBBQFBWood RA, Togias A, Sicherer SH, et al. Omalizumab for the treatment of multiple food allergies. N Engl J Med. 2024;390(10):889–899. doi: 10.1056/NEJMoa2312382 EDN: XYYZVFJin M, Douglass JA, Elborn JS, et al. Omalizumab in allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2023;11(3):896–905. doi: 10.1016/j.jaip.2022.12.012 EDN: IPAGUNPfützner W, Schuppe M. Use of biologics in allergen immunotherapy. Allergol Select. 2021;5:108–118. doi: 10.5414/ALX02206E EDN: VPLVJI